THANK YOU!!
Sending a heartfelt thank you to our incredible NETRF community! Your boundless support and generosity have truly brightened 2023. A special shoutout to our extraordinary friends who hosted fundraisers across the nation and to those who lent their voices to our patient education programs â your contributions are creating a tangible impact. Every gift and act of kindness, whether big or small, makes a significant difference. If you'd like to help ensure the success of NETRF's mission, including our research and patient education efforts, there is still time to donate this year. Let's keep this amazing momentum going in 2024.
With gratitude,
The NETRF Team
| |
Many Ways to Have Impact
As we approach the year's end, there are many ways to make a lasting impact with your tax-deductible gift to NETRF. In addition to traditional cash donations, please consider options such as:
đ Stock Gifts: Donate appreciated securities for a tax-deduction on the full market value and maximize your impact.
đ¤Â Matching Gifts: Double or even triple your impact! Over 20,000 companies match employee donationsâmake your gift go further.
đ°Â IRA Contributions:Â Turn your Individual Retirement Account into a force for good, earn a tax-deduction, and join the NETRF Legacy Society.
đŚÂ Retirement Plan Beneficiary: Support our mission tax-efficiently by naming NETRF as a beneficiaryâbecome a cherished member of the NETRF Legacy Society.
Make your tax-deductible year-end gift now and help our NETRF community thrive!
| |
NETWise: Research Year in ReviewÂ
Research is at the very core of our mission at NETRF. We know research is the key to discovering cures and more effective treatments for neuroendocrine cancers. In this episode of NETWise, we share some of the most important developments in NET research in 2023, reflect on progress thatâs been made, and look ahead to developments on the horizon.Â
| |
Reflection & Preparation
For this month's Thrivership Series, we reflect back and look forward. This episode encourages you to think through the things that worked well this year, while identifying lessons learned. It will also give you an opportunity to gather the tools, support, and resources that you may need as you prepare to thrive with NETs in 2024.
Click here to visit our NET Knowledge Center to access tools and resources for your NET journey in 2024.
| |
|
Celebrating Milestones in NET ResearchÂ
As we reflect on the past year, the Neuroendocrine Tumor Research Foundation (NETRF) takes immense pride in the strides we have made toward understanding and combating neuroendocrine tumors (NETs). Our mission, fueled by the dedication and generosity of our supporters, has been a catalyst for innovation, collaboration, and progress in the field of NET research.
NETRF collects outcomes data for all funded research grants. Through this outcomes data, we gain a stronger understanding of the broad impact NETRF has on neuroendocrine cancer research. We thank our supporters and researchers who drive these outcomes and push the field forward. We are excited to share some of these outcomes with you. Read more here.Â
| |
Recap: NETRF's 2023 Research Symposium
The 2023 Margie & Robert E. Petersen Neuroendocrine Tumor Research Symposium was held on November 15-17, 2023 at the InterContinental Hotel in Boston, Massachusetts. The Symposium is an annual, hallmark event focused on the latest developments in neuroendocrine cancer research. This year's forum brought together 100 brilliant NET minds worldwide and featured a scientific poster session along with oral sessions on personalized medicine, improving radiotheranostics, NET pathways and targets, tumor evolution and microenvironment, and immunotherapies. The presentations outlined current NET research and a Q&A to continue the discussion. The Symposium provides an invaluable platform for networking and forming collaborations to ensure future advancements in the understanding and treatment of neuroendocrine cancer.
| |
Paltusotine Shows Promise in Reducing Key NET Symptoms The initial findings of a Phase 2 study show that the investigational drug paltusotine may significantly reduce both the frequency and intensity of bowel movements and flushing symptoms experienced by those living with carcinoid syndrome.
In addition to reducing two of the key symptoms of the syndrome, the study results showed that paltusotine was well-tolerated by trial participants, according to Crinetics Pharmaceuticals, Inc., which developed and is testing the investigational compound. Read more here.Â
| |
Remembering a Fierce NET WarriorÂ
With a heavy heart, the NETRF community said goodbye to a fearless advocate, Debbie Brickner, in September of 2023. She, along with her sister, Vicki Dailey, tirelessly committed to community outreach and raising funds for a cure through an annual event called Hiking for Debbie (formerly Biking for Debbie). She contributed to the field of NETs research beyond her annual event through her participation in many clinical trials. Just a few days before her passing, Debbie was personally thanked by Dr. Jaydira del Riverio from the National Cancer Institute for her contributions to all future NET patients.
As we remember Debbie, we celebrate the indomitable spirit that defined her. We cannot thank Debbie and her beloved community enough for the advocacy efforts that stretched over more than a decade! In our hearts, her legacy will endureâa testament to the profound impact of a life lived with grace, love, and an unyielding spirit. She will forever be a source of inspiration.Â
| |
|
|
|
|
